Henry Bienen - Onconova Therapeutics Director
ONTXDelisted Stock | USD 7.93 0.00 0.00% |
Director
Dr. Henry S. Bienen, Ph.D., serves as Director of Onconova Therapeutics, Inc., since May 2009. He currently serves as the chairman of Rasmussen College, has served as the president emeritus of Northwestern University since 2009 and served as the president of Northwestern University from 1995 to 2009. Dr. Bienen was the James S. McDonnell Distinguished University Professor and Dean of the Woodrow Wilson School of Public and International Affairs at Princeton University prior to his appointment at Northwestern. Dr. Bienen began his association with Princeton University in 1966, advancing from assistant professor to professor of politics and international affairs, and was then appointed the William Stewart Tod Professor of Politics and International Affairs in 1981 and the James S. McDonnell Distinguished University Professor in 1985. Dr. Bienen has served as a director of Gleacher Company, a publicly held investment banking firm, since May 2010, and the Grosvenor Registered Multi Strategy Fund, LLC, the Grosvenor Registered Multi Strategy Fund, LLC, the Grosvenor Registered Multi Strategy Fund, LLC and the Grosvenor Registered Multi Strategy Master Fund, LLC since April 2011. Dr. Bienen previously served on the boards of directors of The Bear Stearns Companies Inc. until its purchase by JP Morgan Chase Co. in 2008, and SPSS Inc. from 2007 until 2009, when the company was sold to IBM Corporation since 2009.
Age | 75 |
Tenure | 15 years |
Phone | 267 759 3680 |
Web | https://www.onconova.com |
Onconova Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3807) % which means that it has lost $0.3807 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.843) %, meaning that it created substantial loss on money invested by shareholders. Onconova Therapeutics' management efficiency ratios could be used to measure how well Onconova Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
CPA CPA | Sonnet Biotherapeutics Holdings | 75 | |
Randal Chase | GeoVax Labs | 67 | |
Douglas Morris | Bio Path Holdings | 68 | |
Thomas Isett | Ibio Inc | 53 | |
Jose Dorais | Aeterna Zentaris | N/A | |
Patrick Grace | Tonix Pharmaceuticals Holding | 62 | |
Arthur Elliott | Ibio Inc | 81 | |
Kenneth Newport | Aeterna Zentaris | 48 | |
Tomer Kariv | VBI Vaccines | 57 | |
Harriet Robinson | GeoVax Labs | 86 | |
Samuel Saks | Tonix Pharmaceuticals Holding | 62 | |
David Rector | VBI Vaccines | 69 | |
John Spencer | GeoVax Labs | 76 | |
Carolyn Egbert | Aeterna Zentaris | N/A | |
John McKey | Ibio Inc | 74 | |
Ran Nussbaum | VBI Vaccines | 43 | |
Kermit Anderson | Adial Pharmaceuticals | 67 | |
Scott Rocklage | Pulmatrix | 60 | |
Pierre Lapalme | Aeterna Zentaris | 75 | |
Zhi Yang | Jaguar Animal Health | 61 | |
Marcel Aubut | Aeterna Zentaris | N/A |
Management Performance
Return On Equity | -0.84 | |||
Return On Asset | -0.38 |
Onconova Therapeutics Leadership Team
Elected by the shareholders, the Onconova Therapeutics' board of directors comprises two types of representatives: Onconova Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onconova. The board's role is to monitor Onconova Therapeutics' management team and ensure that shareholders' interests are well served. Onconova Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onconova Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Henry Bienen, Director | ||
Ramesh Kumar, Co-Founder, CEO and President and Director | ||
Anne VanLent, Director | ||
Ajay Bansal, CFO and Secretary | ||
Premkumar Reddy, Founder, Lead Scientific Advisor and Director | ||
Jerome Groopman, Director | ||
James Marino, Independent Director | ||
Manoj Maniar, Sr. VP of Product Devel. | ||
Thomas McKearn, President - Research and Development | ||
Abraham Oler, Vice President Corporate Development and General Counsel | ||
Michael Hoffman, Chairman of the Board | ||
Jack Stover, Director | ||
Mark CPA, CFO COO | ||
Victor MD, Chief Officer | ||
Steven Fruchtman, Senior Vice President - Research and Development, Chief Medical Officer | ||
Mark Guerin, Principal Accounting Officer and VP of Financial Planning and Accounting | ||
Steven MD, President CEO | ||
Mark MD, Chief Officer | ||
Viren Mehta, Director | ||
Adar Silverstein, Sr Devel |
Onconova Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onconova Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.84 | |||
Return On Asset | -0.38 | |||
Operating Margin | (89.28) % | |||
Current Valuation | (4.56 M) | |||
Shares Outstanding | 21 M | |||
Shares Owned By Insiders | 0.77 % | |||
Shares Owned By Institutions | 7.95 % | |||
Number Of Shares Shorted | 20.7 K | |||
Price To Earning | (0.87) X | |||
Price To Book | 1.43 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Onconova Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Onconova Therapeutics' short interest history, or implied volatility extrapolated from Onconova Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |